No matches

Educational Resources

How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Dermatology

10 min

expert video

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Pulmonology

5 min

interactivity

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Why Is It Important to Assess Lung Function in Pediatric Asthma?

Pulmonology

5 min

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma?

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Pulmonology

3 min

Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

Pulmonology

52 min

videoanimation

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Dermatology

60 min

slide presentation

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Indirect Treatment Comparison of Biologics Approved for CRSwNP

Rhinology

3 min

expert video

KOL Video Interview – Dr Amy Paller

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region

Educational Resources

How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Why Is It Important to Assess Lung Function in Pediatric Asthma?

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Indirect Treatment Comparison of Biologics Approved for CRSwNP

Head-to-Head Trials of Biologics in CRSwNP

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Amy Paller

Educational Resources

How FeNO Measurement Can Improve Severe Asthma Management — Presented in Spanish by Dr. Miguel Lanz

Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Why Is It Important to Assess Lung Function in Pediatric Asthma?

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP

Indirect Treatment Comparison of Biologics Approved for CRSwNP

Head-to-Head Trials of Biologics in CRSwNP

Type 2 Inflammation: Links With Severe Uncontrolled CRSwNP

KOL Video Interview – Dr Paula Luna

KOL Video Interview – Dr Amy Paller